ABCL: who owns it, and who’s predicted to buy next
Abcellera Biologics Inc · Health Care · on the Prior Moves forward board for 2026-09-30 at rank #33. Research, not investment advice.
Predicted to buy next quarter
3 tracked investors are included in the model-ranked expectations for ABCL in 2026-09-30. This is a forecast about a later filing, not a confirmation that anyone has bought the security or a recommendation to do so.
- Lee Ainslie · Maverick
- Chuck Akre · Akre Capital
- Brad Gerstner · Altimeter
Strongest ranked investor signal: Whale Rock. No calibrated purchase probability is shown.
Currently disclosed holders
No investor in our tracked set discloses ABCL in their latest 13F. The prediction above is a forward call, not a mirror of current holdings.
Mutual fund and ETF holders
12 US mutual funds and ETFs from 10 fund families reported a position in ABCL for the quarter ending 2026-06-30. Against their own report a quarter earlier, 1 raised shares, 4 opened a new position, 6 cut and 0 sold out. Source: SEC Form N-PORT, which funds file about 60 days after quarter end. Share counts, not trades: a change can reflect fund inflows rather than a decision about ABCL.
| Fund family | Funds | Share of fund-held shares |
|---|---|---|
| Smallcap World Fund Inc | 1 | 71.6% |
| Ishares Trust | 1 | 9.0% |
| T. Rowe Price New Horizons Fund, Inc. | 1 | 5.7% |
| Northern Lights Fund Trust Iii | 1 | 5.3% |
| Spdr Index Shares Funds | 2 | 4.0% |
| American Funds Insurance Series | 1 | 1.9% |
| Driehaus Mutual Funds | 1 | 1.3% |
| Northern Funds | 2 | 0.8% |
The predicted next buys, fresh disclosures, and the week’s catalysts. One email a week. Honest numbers, never advice.
See the full ranked board on top picks, how the PriorScore is built on how it works, the honest edge numbers on methodology, and the running accuracy on the prediction leaderboard. Forward quarter 2026-09-30, data as of 2026-10-16. Research, not investment advice, see the disclaimer.